ALNY Alnylam Pharmaceuticals
$223.94 +1.84%
US Stock · Health Care
RSI (14) · 30 / 70 bands
MACD (12, 26, 9)
Solid = close · dashed = 50-day MA · bars = volume. Toggle Bollinger / RSI / MACD. Hover to inspect. EOD data.
1D
+1.84%
YTD
-51.30%
P/E
36.91
P/B
66.57
ROE
93.6%
Div yield
—
Beta
0.4
Market cap
$29.8B
RSI (14)
38
Next earnings
Oct 29, 2026
Previous session
close of Oct 6, 2026 · EOD, no live order bookOpen
$221.02
Close
$223.94
VWAP (n/a)
—
Day high
$229.18
Day low
$217.18
Volume
1.4M
VWAP = daily turnover ÷ volume — the volume-weighted average, the closest EOD read on where trading actually clustered. A true order book is live-only and needs a broker feed. Turnover/VWAP available for MOEX listings.
Latest headlines
AMVUTTRA® (vutrisiran) ‘Play by Play’ Initiative Highlights Former Athletes’ Stories to Shine a Light on the Often-Missed Signs of ATTR-CM
Yahoo Finance · Sep 29
18 of 21 Analysts Still Think Alnylam Stock Is a Buy. Here's Why They're Right.
Yahoo Finance · Sep 28
Alnylam Highlights AMVUTTRA Momentum, Resets 2026 TTR Revenue Outlook
Yahoo Finance · Sep 20
RNA Interference Therapeutics Market Outlook 2026-2035 - Featuring Profiles of Alnylam Pharmaceuticals, Arrowhead Pharmaceuticals, and Silence Therapeutics
Yahoo Finance · Sep 18
Oligonucleotide Therapeutics Market Outlook 2026-2035 - Featuring Profiles of Alnylam Pharmaceuticals, Ionis Pharmaceuticals, and Sarepta Therapeutics
Yahoo Finance · Sep 15
Alnylam's Sell-Off Looks Ugly -- but Wall Street Still Sees a Much Brighter Picture
Yahoo Finance · Sep 15
Headlines via Yahoo Finance · links open the source · not an endorsement.
Recent SEC filings
10-Q Jul 30, 2026 View → 8-K Jul 30, 2026 View → 8-K May 27, 2026 View → 10-Q Apr 30, 2026 View → 8-K Apr 30, 2026 View →
Source: SEC EDGAR · opens the official filing.
Research & reports
External resources — availability and opinions are theirs, not ours.
This is reference data for your own analysis — not a recommendation to buy or sell ALNY. Try it in the Lab to size a position and see the risk.